<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Antithrombin III (Human) (AT III) was administered to 18 patients with documented hereditary AT III deficiency </plain></SENT>
<SENT sid="1" pm="."><plain>In eight patients with no ongoing clinical symptoms of <z:mp ids='MP_0005048'>thrombosis</z:mp>, the percent increase per unit AT III infused per kilogram of body weight ranged from 1.56% to 2.74%, and the half-life from 43.3 to 77.0 hours </plain></SENT>
<SENT sid="2" pm="."><plain>No significant difference was noted between patients receiving and those not receiving <z:chebi fb="2" ids="28794">coumarin</z:chebi> therapy </plain></SENT>
<SENT sid="3" pm="."><plain>In clinically ill patients, the in vivo recovery was significantly lower and ranged from 0.64% to 1.90% increase per unit AT III infused/kg </plain></SENT>
<SENT sid="4" pm="."><plain>Efficacy of AT III was evaluated in 13 patients for the prevention or treatment of <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>AT III was efficacious as assessed by the absence of thrombotic complications after surgery and/or parturition, and the nonextension and nonrecurrence of <z:mp ids='MP_0005048'>thrombosis</z:mp> in patients exhibiting an <z:hpo ids='HP_0011009'>acute</z:hpo> thrombotic episode </plain></SENT>
<SENT sid="6" pm="."><plain>No side effects were noted </plain></SENT>
<SENT sid="7" pm="."><plain>Follow-up studies indicated no <z:hpo ids='HP_0012115'>hepatitis</z:hpo> B seroconversion and no alanine aminotransferase elevations in patients who were not transfused with other blood products </plain></SENT>
</text></document>